Testing STI-8591 for advanced acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This early-stage study tests STI-8591 in people with advanced acute myeloid leukemia (AML) or certain related blood cancers. It mainly aims to find a safe dose and see whether the treatment can work for patients whose disease did not respond to standard care or who cannot get it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent willingly
- Your expected survival is more than 12 weeks
- You have advanced AML or related MDS/MPN-related AML that has failed or is intolerant to standard therapy (or you can’t access standard therapy)
- You are well enough to participate (performance status 0 to 2) and can undergo bone marrow sampling
- Recent blood and organ tests must be within specific limits (liver, kidney, and blood counts, with some allowances for medicines like hydroxyurea)
- You can take oral study medicine and agree to follow study visit schedules and safety rules, including pregnancy prevention if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This Phase 1 trial tests ETH-155008, a new medicine, in adults with relapsed or refractory acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL). It’s mainly designed to see how the treatment works in the body and whether it may help when standard treatment isn’t available or hasn’t worked.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.